BioDelivery Sciences International, Inc. - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

BioDelivery Sciences International, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'BioDelivery Sciences International, Inc. - Product Pipeline Review - 2014', provides an overview of the BioDelivery Sciences International, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioDelivery Sciences International, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioDelivery Sciences International, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioDelivery Sciences International, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BioDelivery Sciences International, Inc.'s pipeline products

Reasons to buy

- Evaluate BioDelivery Sciences International, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioDelivery Sciences International, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioDelivery Sciences International, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioDelivery Sciences International, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioDelivery Sciences International, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioDelivery Sciences International, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
BioDelivery Sciences International, Inc. Snapshot 5
BioDelivery Sciences International, Inc. Overview 5
Key Information 5
Key Facts 5
BioDelivery Sciences International, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
BioDelivery Sciences International, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
BioDelivery Sciences International, Inc. - Pipeline Products Glance 13
BioDelivery Sciences International, Inc. - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
BioDelivery Sciences International, Inc. - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
BioDelivery Sciences International, Inc. - Drug Profiles 17
(buprenorphine + naloxone) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
fentanyl citrate 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
clonidine hydrochloride 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
granisetron 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
BEMA Triptan 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
BioDelivery Sciences International, Inc. - Pipeline Analysis 23
BioDelivery Sciences International, Inc. - Pipeline Products by Target 23
BioDelivery Sciences International, Inc. - Pipeline Products by Route of Administration 25
BioDelivery Sciences International, Inc. - Pipeline Products by Molecule Type 26
BioDelivery Sciences International, Inc. - Pipeline Products by Mechanism of Action 27
BioDelivery Sciences International, Inc. - Recent Pipeline Updates 29
BioDelivery Sciences International, Inc. - Dormant Projects 33
BioDelivery Sciences International, Inc. - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
amphotericin B 34
BioDelivery Sciences International, Inc. - Company Statement 35
BioDelivery Sciences International, Inc. - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
BioDelivery Sciences International, Inc., Key Information 5
BioDelivery Sciences International, Inc., Key Facts 5
BioDelivery Sciences International, Inc. - Pipeline by Indication, 2014 7
BioDelivery Sciences International, Inc. - Pipeline by Stage of Development, 2014 8
BioDelivery Sciences International, Inc. - Monotherapy Products in Pipeline, 2014 9
BioDelivery Sciences International, Inc. - Combination Treatment Modalities in Pipeline, 2014 10
BioDelivery Sciences International, Inc. - Out-Licensed Products in Pipeline, 2014 11
BioDelivery Sciences International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
BioDelivery Sciences International, Inc. - Pre-Registration, 2014 13
BioDelivery Sciences International, Inc. - Phase III, 2014 14
BioDelivery Sciences International, Inc. - IND/CTA Filed, 2014 15
BioDelivery Sciences International, Inc. - Preclinical, 2014 16
BioDelivery Sciences International, Inc. - Pipeline by Target, 2014 24
BioDelivery Sciences International, Inc. - Pipeline by Route of Administration, 2014 25
BioDelivery Sciences International, Inc. - Pipeline by Molecule Type, 2014 26
BioDelivery Sciences International, Inc. - Pipeline Products by Mechanism of Action, 2014 28
BioDelivery Sciences International, Inc. - Recent Pipeline Updates, 2014 29
BioDelivery Sciences International, Inc. - Dormant Developmental Projects,2014 33
BioDelivery Sciences International, Inc. - Discontinued Pipeline Products, 2014 34
BioDelivery Sciences International, Inc., Subsidiaries 38